Liposomal alendronate for the treatment of restenosis

Dikla Gutman, Gershon Golomb*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

34 Scopus citations

Abstract

The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or drug eluting stent (DES). The advent of DES systems has effectively allayed much of the challenge of restenosis that has plagued the success of percutaneous coronary interventions (PCI). However, there are certain limitations to DES use, among which is late stent thrombosis. Innate immunity and inflammation are of major importance in the overreaction of the wound healing response to PCI-induced vascular injury, which leads to restenosis. Liposomes containing alendronate have been shown to deplete circulating monocytes and reduce experimental restenosis. This review presents a unique systemic approach for treating restenosis with alendronate liposomal nano-carriers and reports on its formulation development, formulation variables affecting monocyte/macrophage targeting, pharmacokinetics (PK) and biodistribution, in vitro and in vivo anti-inflammatory effect, and the recent results of the phase II clinical trial.

Original languageEnglish
Pages (from-to)619-627
Number of pages9
JournalJournal of Controlled Release
Volume161
Issue number2
DOIs
StatePublished - 20 Jul 2012

Keywords

  • Bisphosphonate
  • Inflammation
  • Liposome
  • Monocytes/macrophages
  • Restenosis

Fingerprint

Dive into the research topics of 'Liposomal alendronate for the treatment of restenosis'. Together they form a unique fingerprint.

Cite this